

DT12 Rec'd PCT/PTO 03 JAN 2005

ATTORNEY DOCKET NO. 0253.410US/16384US04

IN THE UNITED STATES  
PATENT AND TRADEMARK OFFICE

In the Application of:

Van Den Hazel, et al.

Serial No.:

Filed: January 03, 2005

Int Filing Date: 06/23/03


Int. App. No. PCT/DK 03/000426

For: "Full-Length Interferon Gamma  
Polypeptide Variants"

## CERTIFICATE OF MAILING

I hereby certify that this paper (and all  
papers referred to herein) is being  
deposited with the United States Postal  
Service as first class mail, postage prepaid,  
in an envelope addressed to: MAIL STOP  
PCT, Commissioner for Patents, P.O. Box  
1450, Alexandria, VA 22313-1450 on:

January 03, 2005



Donald J. Pochopien  
Registration No. 32,167  
Attorney for Applicants

## STATEMENTS UNDER 37 C.F.R. § 1.821 AND 1.825

MAIL STOP PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sirs:


Pursuant to 37 C.F.R. § 1.821 and 1.825, the undersigned attorney hereby states that the content of the paper copy of the substitute SEQUENCE LISTING, a copy of which is attached hereto, and the content of the computer readable form (CRF) of the substitute SEQUENCE LISTING, a copy of which is attached hereto, are the same.

Pursuant to 37 C.F.R. § 1.821 and 1.825, the undersigned attorney hereby states that the content of the substitute SEQUENCE LISTING does not add new matter. Support for the sequences corresponding to SEQ ID NOS: 1-12 of the substitute SEQUENCE LISTING are found in SEQ ID NOS: 1-12, respectively, of the originally filed SEQUENCE LISTING. Support for the newly added sequence corresponding to SEQ ID NO: 13 is found in the published specification at page 78, line 14. For these reasons, the substitute SEQUENCE LISTING does not add new matter.

Respectfully submitted,

**McANDREWS, HELD & MALLOY, LTD.**

By:



Donald J. Pochopien

Registration No. 32,167

Attorney for Applicants

500 West Madison Street, 34<sup>th</sup> Floor

Chicago, Illinois 60661

(312) 775-8133

Date: January 03, 2005

J:\open\jip\Codexis\16384US04\16384US04 Statement 1.821-5.doc